Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia

ConclusionOur study showed a significantly better ORR with ATG-CsA than other regimens for treatment of AA in elderly, with more complications but no more death. Age per se is not a limiting factor for treatment with ATG-CsA: this regimen should be used as first-line treatment in elderly patients if they have a good performance status and low comorbidity index score. Among patients with adverse performance status or comorbidities contra-indicating the use of ATG, CsA alone or in combination may be safely used. Other strategies might be reserved for later courses of treatments. Supportive care may have a great impact on survival in this population.DisclosuresAdes: JAZZ: Honoraria; Takeda: Membership on an entity's Board of Directors or advisory committees; silent pharma: Consultancy; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Peffault De Latour: Pfizer Inc.: Consultancy, Honoraria, Research Funding; Amgen Inc.: Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Contejean, A., Resche-Rigon, M., Tamburini, J., Alcantara, M., Jardin, F., Lengline, E., Ades, L., Bouscary, D., Marcais, A., Lebon, D., Molucon-Chabrot, C., Terriou, L., Barraco, F., Banos, A., Bussot, L., Cahn, J.-Y., Hirsch, P., Maillard, N., Simon, L. Tags: 508. Bone Marrow Failure: Poster I Source Type: research